Kei Kishimoto

Company: Selecta Biosciences Inc.

Job title: CSO

Seminars:

Industry Leaders Panel Discussion: Addressing High Dose AAV Delivery 9:30 am

Have we reached the highest dose for gene therapy yet? Exploring dosing strategies: “One and done or Slower and Lower?” What impact would a cumulative vector genome delivery approach have on safety and efficacy? Moving away from one and done: what does best practice look like for dosing strategies? Which role does complement play in…Read more

day: Day One

Addressing the Multifaceted Nature of AAV Immunogenicity 9:00 am

Immunogenicity of AAV is complex and challenging, involving elements of innate, humoral and cellular immunity that can adversely impact patient eligibility, safety, efficacy, durability of treatment, and ability to re-dose Mitigation strategies should account for all aspects of immunogenicity Discussing data on the effects of ImmTOR tolerogenic nanoparticles on innate, CD8 T cell, and antibody…Read more

day: Day One